Celyad Oncology Provides an Update on Its Strategic Business Model, Continuing to Focus on Opportunities to Fully Harness the True Potential of Its Proprietary Technology Platforms and Intellectual Property – Yahoo Finance

MONT-SAINT-GUIBERT, Belgium, December 21, 2022–(BUSINESS WIRE)–Regulatory News:
Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company") (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today provides an update on its Celyad 2.0 business strategy which has been adopted and implemented over the last few months.
In keeping with this strategy, the Company intends to focus on maximizing its valuable intellectual property (IP) estate, and strengthening its research focus.
The Company has compiled a foundational and broad IP estate that controls key aspects of developing therapies in the allogeneic cell therapy space. The patents around allogeneic CAR T-cell therapies and NKG2D-based therapies provide an avenue to develop intellectual property programs and to partner with outside parties around the licensing of these patents.
In addition to IP partnering transactions, Celyad 2.0 will prioritize discovery research in areas of expertise where it can leverage the differentiated nature of its platforms. The Company is implementing a differentiated and innovative strategy, tackling the major current limitations of CAR T-cell therapies. This strategy includes:
Multiplexing approach of the short hairpin RNA (shRNA) platform, allowing multiple genes, including essential and functional genes, to be modulated simultaneously;
Dual CAR development of a next-generation NKG2D-based CAR which may help to overcome resistance and immune escape often observed with traditional single targeting approaches; and
Development of B7-H6-targeting immunotherapies as the Company believes that B7-H6 is an underappreciated target that could change the paradigm of cell therapy due to its broad expression in a large variety of cancers.
Celyad Oncology is of the opinion that it will potentially create more shareholder value by licensing its patent estate and further strengthening its research efforts to improve the differentiated nature of its platforms.
Based on a strategic and financial review, the Company has decided to discontinue the development of its remaining clinical program CYAD-211 (the allogeneic shRNA-based, anti-BCMA CAR T candidate for relapsed or refractory multiple myeloma (r/r MM)). There were no safety concerns leading to this decision and all patients previously treated with CYAD-211 will continue to receive their protocol-defined follow-up.
The key data points of the program are as follows:
19 r/r MM patients have been treated with CYAD-211 in the IMMUNICY-1 trial which was developed to validate shRNA technology in the clinic;
The observed safety profile, including the lack of observed Graft-versus-Host disease, provides proof-of-concept for the use of shRNA technology for allogeneic CAR Ts;
Out of 17 evaluable patients, a partial response was achieved in five patients. One patient was recently re-treated with a second dose of CYAD-211 after having reached stable disease post first infusion; and
Enhanced lymphodepletion did not seem to improve clinical activity nor persistence of the cells post-infusion.
Anticipated milestones for 2023
The Company will take part in several conferences including The World Oncology Cell Therapy Congress in April and the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in November; and
The Company will provide updates on the potential proof-of-concept of the dual CAR and multiplexing research programs and on business development in the second quarter of 2023.
About Celyad Oncology
Celyad Oncology is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies. Celyad Oncology is based in Mont-Saint-Guibert, Belgium and New York, NY. For more information, please visit
Celyad Oncology Forward-Looking Statement
This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding beliefs about and expectations for the Company’s updated strategic business model, including associated potential benefits, transactions and partnerships, and statements regarding the potential value of the Company’s IP. The words "will," "believe," "potential," "continue," "target," "could" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management’s current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to the material uncertainty about the Company’s ability to continue as a going concern; the Company’s ability to realize the expected benefits of its updated strategic business model; the Company’s ability to develop its IP assets and enter into partnerships with outside parties; the Company’s ability to enforce its patents and other IP rights; the possibility that the Company may infringe on the patents or IP rights of others and be required to defend against patent or other IP rights suits; the possibility that the Company may not successfully defend itself against claims of patent infringement or other IP rights suits, which could result in substantial claims for damages against the Company; the possibility that the Company may become involved in lawsuits to protect or enforce its patents, which could be expensive, time-consuming, and unsuccessful; the Company’s ability to protect its IP rights throughout the world; the potential for patents held by the Company to be found invalid or unenforceable; and other risks identified in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
View source version on
Celyad Oncology Investor and Media Contact:
Celyad Oncology
Related Quotes
Blue Jackets drop fifth straight in 5-3 loss to Flyers: 'We were sloppy and it cost us straight to the end'
Food prices were up 69.8% in November, while non-food inflation was 60.4%, the Department of Census and Statistics of the crisis-struck nation said in a statement. Sri Lanka has been struggling with soaring inflation for nearly a year, partly triggered by its worst financial crisis in seven decades and an ill-thought out ban on chemical fertilizer implemented last year, which has since been reversed. Central Bank of Sri Lanka Governor Nandalal Weerasinghe predicted that if the current trend of monetary policy was followed, inflation could drop to 4%-5% by the end of next year.
(Bloomberg) — Chinese President Xi Jinping exchanged congratulatory messages with his Australian counterpart to mark the 50th anniversary of diplomatic relations, the latest sign of warming ties between the two major trade partners.Most Read from BloombergMusk Will Resign as Twitter CEO and Focus on EngineeringMusk Lashes Out at Unhappy Investor as Tesla Shares RetreatMessi Evacuated by Helicopter After Crowds Swarm World Cup WinnersAmazon Ring Cameras Used in Nationwide ‘Swatting’ Spree, US Sa
The voices issuing warnings of an impending recession have been growing louder. The feeling on Wall Street is that one is all but inevitable right now. One prominent name to wade in on the matter is billionaire David Rubenstein. The Carlyle Group co-founder believes that due to the current economic environment of "jacked up" interest rates, gross domestic product growth is set to decelerate, bringing in to play a recession. Not only that, but he also thinks the Fed is unlikely to put the brakes
Yahoo Finance Live anchor Dave Briggs looks to Carnival Cruise Line's stock ahead of its latest earnings report due out before tomorrow's closing bell.
These rock-solid income stocks, with inflation-fighting yields ranging from 4.6% to 8%, provide plenty of reward with minimal risk for investors.
As much as we'd like the stock market to increase in value every year, corrections, crashes, and bear markets are a more common occurrence than most people probably realize. In 2022, investors have dealt with all three major U.S. stock indexes plunging into respective bear markets. On the bright side, bear markets have a reputation for allowing investors to buy high-quality stocks at a discount.
(Bloomberg) — Elon Musk pushed back on criticism from one of Tesla Inc.’s most vocal supporters amid growing concern about the chief executive officer’s ability to manage Twitter Inc. and his other businesses.Most Read from BloombergMusk Will Resign as Twitter CEO and Focus on EngineeringMusk Lashes Out at Unhappy Investor as Tesla Shares RetreatMessi Evacuated by Helicopter After Crowds Swarm World Cup WinnersAmazon Ring Cameras Used in Nationwide ‘Swatting’ Spree, US SaysTrump’s Tax Records t
Corporate earnings are set to take a hit and Wall Street isn't properly anticipating it, Morgan Stanley's Mike Wilson warns. And when earnings fall, so will stocks.
The big market headline this year – all year – has been the steady fall in stocks. The S&P 500 is down 20% for 2022, and the NASDAQ has fallen a disastrous 33%. And while recent data shows that there may be some hope on the inflation front, there may still be storm clouds massing for next year’s stock market. That’s the view of Mike Wilson, Morgan Stanley's chief equity strategist. He’s been a leading voice among the bears this year, and he’s not changing that tune as we head into the New Year.
In this article, we discuss 12 best affordable stocks to buy under $5. If you want to see more stocks in this selection, check out 5 Best Affordable Stocks to Buy Under $5. Third Point, a New York-based financial advisor, published its third-quarter 2022 investor letter back in October, in which the fund highlighted its market […]
Most everyone loves an early holiday present. And for some real estate investment trust (REIT) investors, that early gift came in the form of a dividend increase over the past two weeks. Of course, a dividend increase is great because it puts more income into the pockets of investors and increases the yield on their purchase price, but more importantly, a dividend increase also signals to the markets that the company expects to perform well, perhaps generating increases in revenue and funds from
Why Palantir is my favorite stock in the technology industry
The average brokerage recommendation (ABR) for Energy Transfer LP (ET) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Phew. The S&P 500's horrible year that was 2022 is finally just about over. And analysts have picked their favorite spots.
In this article, we discuss 11 best aerospace stocks to buy. If you want to see more stocks in this selection, check out 5 Best Aerospace Stocks To Buy. Economic recovery for the aerospace and defense sector gained momentum in 2022 on the back of increasing demand for air travel. As per an outlook survey […]
Monster growth stocks have the power to keep outperforming the market year after year, and that's why practically everyone loves to have them in their portfolios. Let's dive in and explore what that means so you'll get the hang of how to hunt potential monster growth stocks intelligently. The first trick to finding tremendous growth stocks is to look in the places you're most likely to find them: immature industries.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Apple Inc…
Intel (NASDAQ: INTC) is enduring a painful year. Because of worsening economic conditions, the semiconductor manufacturer's revenue tumbled 20% in the third quarter, while its earnings plummeted even further. This painful situation led Intel to seek outside-the-box ways to finance its growth to maintain its balance sheet strength and investor payout.
Higher rates are attracting more individual investors to the preferred stock market, and REITS are a relatively small subset.


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button